Menu

Incyte will no longer allow 340B hospitals to have direct delivery of Opzelura products purchased at the 340B discount price to contract pharmacies.

Incyte Becomes 26th Drugmaker to Place Contract Pharmacy Restrictions

September 21, 2023 Rich Daly Editor in Chief Views

Drug manufacturer Incyte Corp. this week announced it will become the 26th drug manufacturer to restrict access to 340B pricing when [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Rich Daly